Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesaglitazar Long-Term Extension in Type 2 Diabetes (GALLEX 6)
NCT00226330Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Mar 2005
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of tesaglitazar in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Mar 2005; status: terminated.
02
Drugs
tesaglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00226330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00226330.